ThinkSono and NYU Langone Health Collaborate on AI Ultrasound Software Trial for DVT Detection

NYU Langone Health Research staff ● Left: Moira McGevna, right: Giancarlo Speranza, not pictured: Dr. Amir Mullick, Gina Bernardez, Keerthi Harish, Dr Glenn Jacobowitz. ThinkSono Guidance App (right) and a compatible handheld ultrasound device (left) ● Photo Credit: SOLJETS

LONDON, England, November 3, 2023 (VSNewsNetwork.com) - In a significant move to advance medical technology, ThinkSono Ltd, an innovator in ultrasound AI, has initiated the first U.S. clinical trial of its ThinkSono Guidance software at NYU Langone Health. This AI-powered technology aims to transform the diagnosis of deep vein thrombosis (DVT), a serious condition leading to the hospitalization of up to 300,000 Americans annually.

Video: AutoDVT - AI for detection of blood clots via ThinkSono

DVT, characterized by blood clot formation in the veins, can result in critical outcomes such as pulmonary embolism (PE) or post-thrombotic syndrome if not promptly diagnosed and treated. NYU Langone's vascular surgeons, who are recognized for their expertise in venous diseases and clinical trials, are at the forefront of this pioneering study.

The ThinkSono Guidance System utilizes artificial intelligence to potentially identify DVT with greater speed, precision, and cost efficiency than conventional diagnostic methods. Dr. Glenn Jacobowitz, a distinguished vascular and endovascular surgeon at NYU Langone, and President of the American Venous Forum, is the principal investigator of the study. "An effective ultrasound guidance technology would be a powerful tool in our diagnostic arsenal," Dr. Jacobowitz states, underlining the potential transformative impact on patient care.

The trial will involve medical students from NYU Grossman School of Medicine, including participants from its MD/MBA program like Giancarlo Speranza and Keerthi Harish. The study aims to compare the performance of ThinkSono Guidance System scans with traditional ultrasound scans to establish the accuracy of the AI system.

The research endeavor seeks not only to validate the ThinkSono technology but also to explore how AI-enhanced solutions can be integrated into daily clinical practices. The findings are expected to contribute significantly to medical research and future FDA submissions.

Dr. Thomas Maldonado, Medical Director of the NYU Langone Venous Thromboembolic Center, emphasizes the importance of research with practical implications, expressing confidence in the trial's contribution to patient care and medical education. Fouad Al Noor, CEO of ThinkSono, echoes this sentiment, highlighting the partnership's role in adopting innovative AI solutions in healthcare.

For more information on the study and ThinkSono Guidance technology, please visit www.thinksono.com.

Source: ThinkSono Ltd via Newswire